These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19530253)

  • 1. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
    Liu G; Taylor SA; Marrinan CH; Hsieh Y; Bishop WR; Kirschmeier P; Long BJ
    Int J Cancer; 2009 Dec; 125(11):2711-20. PubMed ID: 19530253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
    Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
    Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
    Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
    Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
    Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
    Gravina GL; Marampon F; Petini F; Biordi L; Sherris D; Jannini EA; Tombolini V; Festuccia C
    Endocr Relat Cancer; 2011 Aug; 18(4):385-400. PubMed ID: 21551258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.
    Neschadim A; Pritzker LB; Pritzker KP; Branch DR; Summerlee AJ; Trachtenberg J; Silvertown JD
    Endocr Relat Cancer; 2014 Jun; 21(3):459-71. PubMed ID: 24812057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
    Liu G; Marrinan CH; Taylor SA; Black S; Basso AD; Kirschmeier P; Robert Bishop W; Liu M; Long BJ
    Anticancer Drugs; 2007 Sep; 18(8):923-31. PubMed ID: 17667598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
    Guérin O; Formento P; Lo Nigro C; Hofman P; Fischel JL; Etienne-Grimaldi MC; Merlano M; Ferrero JM; Milano G
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):51-7. PubMed ID: 17593391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
    Dalrymple SL; Becker RE; Isaacs JT
    Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
    Sakai I; Miyake H; Terakawa T; Fujisawa M
    Cancer Sci; 2011 Apr; 102(4):769-75. PubMed ID: 21214673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
    Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH
    Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
    Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
    Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.
    Dahmani A; de Plater L; Guyader C; Fontaine JJ; Berniard A; Assayag F; Beuzeboc P; Marangoni E; Némati F; Poupon MF; Pasik C; Oudard S; Decaudin D
    Anticancer Drugs; 2010 Nov; 21(10):927-31. PubMed ID: 20827173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
    Van Laar ES; Weitman S; MacDonald JR; Waters SJ
    Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
    Hwang JJ; Kim YS; Kim MJ; Kim DE; Jeong IG; Kim CS
    J Urol; 2010 Dec; 184(6):2557-64. PubMed ID: 21030039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
    Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.